-
公开(公告)号：US20240360445A1
公开(公告)日：2024-10-31
申请号：US18643535
申请日：2024-04-23
IPC分类号： C12N15/113 , A61P35/00
CPC分类号： C12N15/113 , A61P35/00 , C12N2310/14 , C12N2310/16 , C12N2310/335
摘要： Inhibitory RNA molecules that specifically inhibit mammalian RIZ2 expression, with therapeutic effect in cell proliferative diseases, such as cancer.
-
公开(公告)号：US20240360427A1
公开(公告)日：2024-10-31
申请号：US18473042
申请日：2023-09-22
发明人： Brent E. STEAD
CPC分类号： C12N9/22 , A61K48/0066 , A61P35/00 , C12N15/102 , C12N15/111 , C12N2310/20
摘要： Provided herein are compositions and methods of using chimeric nucleases comprising an I-TevI nuclease domain and a Cas domain for the targeting of oncogenes.
-
公开(公告)号：US20240360413A1
公开(公告)日：2024-10-31
申请号：US18755134
申请日：2024-06-26
IPC分类号： C12N5/0783 , A61K35/17 , A61K39/00 , A61K39/245 , A61K45/06 , A61P35/00 , C12N7/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K39/245 , A61K45/06 , A61P35/00 , C12N7/00 , A61K2039/572 , A61K2039/585 , C12N2501/04 , C12N2501/2315 , C12N2501/2321 , C12N2501/42 , C12N2501/599 , C12N2502/1121 , C12N2502/1157 , C12N2502/1352 , C12N2710/16134
摘要： This disclosure describes an adaptive NK cell, an isolated population of adaptive Natural Killer (NK) cells, a composition including an adaptive NK cell, and methods for producing, preparing, and using an adaptive NK cell or an isolated population or composition including an adaptive NK cell. The adaptive NK cells may be used to treat a viral infection or a tumor.
-
公开(公告)号：US20240360247A1
公开(公告)日：2024-10-31
申请号：US18438286
申请日：2024-02-09
发明人： Subroto Chatterjee
IPC分类号： C07K16/40 , A61K39/00 , A61K45/06 , A61P35/00 , G01N33/573
CPC分类号： C07K16/40 , A61K45/06 , A61P35/00 , G01N33/573 , A61K2039/505 , C07K2317/24 , C07K2317/30 , G01N2800/52
摘要： Compositions in the prevention and treatment of cancers, such as colorectal cancer or diseases associated with abnormal levels of β-1,4-galactosyltransferase-V (β-1,4-GalT-V), include at least one inhibitor of glycosphingolipid synthesis.
-
公开(公告)号：US20240360239A1
公开(公告)日：2024-10-31
申请号：US18644984
申请日：2024-04-24
发明人： Hergen SPITS , Paula Maria Wilhelmina VAN HELDEN , Remko SCHOTTE , Wouter POS , Christien FATMAWATI , Danïel Michiel GO , Koen WAGNER , Julien Christian VILLAUDY
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , C07K14/705 , G01N33/574
CPC分类号： C07K16/2896 , A61P35/00 , C07K14/70596 , C07K16/2818 , G01N33/57492 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/34 , C07K2317/54 , C07K2317/73 , C07K2317/732 , C07K2317/734 , G01N2333/70596
摘要： The present invention provides novel binding compounds and therapeutic applications thereof.
-
公开(公告)号：US20240360216A1
公开(公告)日：2024-10-31
申请号：US18688387
申请日：2021-09-14
发明人： Huaxing ZHU , Zuowei SONG , Debin LI , Futao YU , Zhaofeng QIN , Jixuan FANG , Mi WANG
CPC分类号： C07K16/2809 , A61K47/6849 , A61P35/00 , G01N33/6854 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/567 , C07K2317/92 , G01N2333/7051
摘要： Provided is a novel anti-CD3 humanized antibody. The anti-CD3 humanized antibody can specifically bind to human and monkey CD3 proteins, and said antibody has good biological activity.
-
7.发明公开公开(公告)号：US20240360089A1
公开(公告)日：2024-10-31
申请号：US18585551
申请日：2024-02-23
IPC分类号： C07D277/82 , A61P35/00 , C07D277/54
CPC分类号： C07D277/82 , A61P35/00 , C07D277/54
摘要： HDAC inhibitor compounds having trifluoromethylpyruvamides or hydrates thereof, and methods of making and using the same, are described. The HDAC inhibitor compounds are useful for inhibiting HDAC activity and inhibiting growth of cancer cells.
-
公开(公告)号：US20240358832A1
公开(公告)日：2024-10-31
申请号：US18763813
申请日：2024-07-03
发明人： Guideng LI , Hongcheng CHENG , Yajing QIU , Yue XU
IPC分类号： A61K39/00 , A61P35/00 , C07K14/725 , C12N5/0783 , C12N15/10 , C12N15/86
CPC分类号： A61K39/4632 , A61K39/4611 , A61K39/464499 , A61P35/00 , C07K14/7051 , C12N5/0636 , C12N15/1024 , C12N15/86 , A61K2239/26 , C12N2510/00 , C12N2740/10043
摘要： Construction of a T cell receptor and the use thereof are provided. Utilizing mutations of intracellular constant region sites of an α chain and an β chain of the T cell receptor to inhibit the degradation of the T cell receptor after TCR antigen signal activation, maintain the level of TCR on cell surface, and improve the efficacy of TCR-T cell therapy. This method can be applied to different TCR-T cell therapies.
-
公开(公告)号：US20240358830A1
公开(公告)日：2024-10-31
申请号：US18684155
申请日：2022-08-19
发明人： Young Jik Kwon , Jee Young Chung
CPC分类号： A61K39/4622 , A61K35/15 , A61K39/39 , A61K39/4615 , A61K39/4644 , A61P35/00 , C12N5/163
摘要： The disclosure provides compositions, preparations, and methods comprising cell-derived vesicles induced using a blebbing agent from a hybridoma of a dendritic cell and a target cell, and uses thereof, including as a means to modulate a subject's immune system.
-
公开(公告)号：US20240358797A1
公开(公告)日：2024-10-31
申请号：US18656385
申请日：2024-05-06
发明人： Monia DRAGHI , Rudy CHRISTMAS , Cafer OZDEMIR , Burak YILMAZ , Yusuf ERKUL , Manfred KRAUS
CPC分类号： A61K38/212 , A61K9/5123 , A61K38/1709 , A61K38/2013 , A61K38/208 , A61K38/2086 , A61K48/005 , A61P35/00
摘要： The present disclosure provides technologies for achieving treatment of cancer. The present disclosure provides methods and compositions for the treatment of cancer using oncoselective construct designs that can be used to encode payloads of high therapeutic interest. The present disclosure recognizes that treatment of individuals suffering from cancer with engineered nucleic acids of the disclosure in combination with immune checkpoint therapy provides unique advantages.
-
-
-
-
-
-
-
-
-
搜索结果
60009 条记录 (耗时 0.064 秒)
